Abstract: A recombinant vector comprising capsid proteins derived from simian adenovirus Pan5, Pan6, Pan7, SV1, SV25 or SV39 sequences are described. These vectors contain a heterologous gene under the control of regulatory sequences packaged in the capsid. A cell line which expresses simian adenovirus gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.

Abstract: An isolated, purified or recombinant nucleic acid sequence is disclosed, comprising: (a) a sequence that encodes both an angiogenic factor antagonist and a vascular endothelial structure regulator; (b) a sequence substantially homologous to or that hybridizes to sequence (a) under stringent conditions; or (c) a sequence substantially homologous to or that hybridizes under stringent conditions to the sequence (a) or (b) but for the degeneracy of the genetic code; or (g) an oligonucleotide specific for any of the sequences (a), (b) or (c). Particular oligonucleotides (d) are those encoding the vascular endothelial structure regulator. Also described are methods for preparing the recombinant polynucleotide, proteins encoded by such polynucleotides and their use in gene or protein therapy for the treatment of conditions such as cancer.

Abstract: The present invention provides new Pestiviral RNA genomes (replicons) that are able to replicate, and can be packaged into infectious viral particles in cells that complement the missing protein(s), but do not produce infectious progeny virus. Such replicons can be useful for vaccine purposes.

Abstract: The present invention relates to a defective adenovirus comprising at least a DNA sequence coding for all or an active part of glutathione peroxidase or a derivative thereof. It also relates to their utilization in therapy and to the corresponding pharmaceutical compositions.

Abstract: The present invention discloses the use of a mutant Leishmania as a suicidal vaccine wherein the mutant Leishmania is responsive to external signals to become porphyric and commit suicidal cytolysis. The mutant can be selected from natural Leishmania species or constructed by genetic engineering.

Abstract: The invention relates to adenoviral vectors. More particularly, this invention relates to recombinant high capacity adenoviral vectors which can be employed in the treatment of hemophilia A, as well as methods and process for their creation and use.

Abstract: The present invention relates to novel human coagulation Factor VII polypeptides, Factor VII derivatives as well as polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

Abstract: A bidirectional module for activation of gene expression and regulation of transcription in both directions is disclosed. The bidirectional module comprises multiple cis regulatory DNA sequence elements, strategically arranged to give a ‘Transcription Activating Module’ that achieves high level expression from a ‘Transcription Initiation Module’. The latter functions like a minimal promoter. The former activates transcription simultaneously in both the directions from the latter and also responds to several transcription inducing, external stimuli in both the directions. Since it is an artificially designed bidirectional transcription module, it has no equivalent DNA sequence in plant genome. This reduces the chances of the genes from being silenced by homology based mechanisms. A bidirectional promoter module as this, can therefore be used to develop efficient vectors for genetic engineering in plants.

Abstract: The present invention provides polynucleotides isolated from eucaryotic organisms which are structural genes or promoters. Such isolated polynucleotides are particularly useful in the modification of gene expression in plants. This invention also relates to compositions isolated from plants and their use in the modification of gene activation and/or expression. In a specific embodiment, the subject invention provides plant polynucleotide sequences encoding promoters that are components of the cellular activation and transcription apparatus and the use of such polynucleotide sequences in the modification of expression of genes.

Abstract: Described is a double-transfected cell line containing (a) a DNA sequence encoding an uptake transporter for organic anions, preferably OATP8, operatively linked with a promoter and (b) a DNA sequence encoding an export pump for organic anions or anionic conjugates, preferably the multidrug resistance protein 2 (MRP2), operatively linked with a promoter. Moreover, various uses of said cell line are described, preferably its use for the identification of transport inhibitors, e.g. drug candidates.

Abstract: The invention relates to methods of optimizing gamma carboxylation of a vitamin K-dependent protein, methods of generating fully gamma carboxylated vitamin K-dependent protein, and compositions comprising chimeric nucleic acids and proteins for use in treatment of vitamin K-dependent disease states.

Abstract: The present invention provides an isolated nucleic acid comprising a single retroviral LTR, a polypurine tract, a packaging signal, a primer binding site and a rev responsive element. Further provided is an isolated nucleic acid comprising a heterologous nucleotide sequence, a single retroviral long terminal repeat (LTR), a packaging signal, a rev responsive element, a polypurine tract, a eukaryotic promoter, a primer binding site, a bacterial origin of replication and a bacterial selection marker. In addition, the present invention provides an isolated nucleic acid comprising a 5? retroviral LTR and a 3? retroviral LTR, a heterologous nucleotide sequence, a packaging signal, a rev responsive element, a polypurine tract, a eukaryotic promoter, a primer binding site, a bacterial origin of replication and a bacterial selection marker cassette, wherein the bacterial origin of replication and bacterial selection marker are located between the two LTRs.

Abstract: The invention features substantially pure nucleic acid sequences encoding wild-type or mutant serotonin reuptake transporter (SERT) polypeptides, as well as the polypeptides themselves. The invention also features methods for identifying modulators of the biological activity of a SERT and for identifying if such a modulator has a secondary target. In addition, the invention features methods for treating a condition in a subject.

Abstract: Methods of treating an individual who has a disease or disorder associated with one or more genetic mutations or undesirable alleles in genomic DNA of the individual, or preventing an individual from developing a disease or disorder associated with one or more genetic mutations or undesirable alleles in genomic DNA of the individual, by replacing a segment of genomic DNA that has a mutated sequence or undesirable allele with a corresponding segment of DNA that has a non-mutated sequence or desirable allele, are disclosed. Methods of inducing tolerance and preventing transplant rejection in a recipient, methods of inducing tolerance and or reducing allergies are disclosed and method of increasing fertility in a woman are disclosed. Each of the methods comprises replacing a segment of genomic DNA in an individual with a corresponding segment of DNA from another. An apparatus for doing large scale PCR preparations is disclosed.

Abstract: The present invention provides methods and compounds for altering remodeling of chromatin in a cell.

Abstract: Described is a novel process for the production of at least one protein of interest by secretion of the protein of interest from a pro- or eukaryotic host cell in a compartment system, which host cell is stably expressing a secretion system and capable of heterologous secretion of the protein of interest and which compartment system has at least a first and a second compartment and wherein the host cell is located in the first compartment and wherein the first and second compartment are separated from each other by a barrier, wherein the barrier is permeable for the secreted protein of interest, but not permeable for the host cell.

Abstract: The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.

Abstract: Sequences of a serotype 9 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV9-mediated delivery of therapeutic and immunogenic genes is also provided.

Abstract: Protein synthesis inhibitor resistance genes (typified by a cycloheximide resistance gene) are capable of imparting resistance to a protein synthesis inhibitor (typified by cycloheximide) to animal cells sensitive to the inhibitor. The genes have a sequence mutated by substitution in a gene encoding a ribosome-constituting protein derived from an animal. The genes may be placed in recombinant vectors, including expression vectors containing the gene together with a foreign protein structural gene.

Abstract: The present invention provides methods for generating and identifying mutations in Caenorhabditis elegans. Disclosed herein are methods for introducing DNA into the C. elegans germline, methods for expressing DNA in the C. elegans germline, and methods for generating C. elegans mutants by using controlled mobilization of endogenous and heterologous transposons. Also disclosed are a transgene construct for expression in C. elegans and methods for inserting single copy DNA sequences into the C. elegans germline, and engineering mutations into the C. elegans genome.